Table 1.
Baseline characteristics
| Parameters | Patients (N = 99) |
|---|---|
| Age (years) | 57.98 ± 10.33 |
| Gender (Male/Female) | 89/10 |
| Hepatitis history | |
| No hepatitis history (n/%) | 3 (3.1) |
| HBV (n/%) | 94 (94.9) |
| HCV (n/%) | 2 (2.1) |
| Drink (n/%) | 43 (43.4) |
| Cirrhosis (n/%) | 55 (55.6) |
| Tumor distributiona (%) | 20.0 (5.0–30.0) |
| Number of nodules | |
| 1 (n/%) | 30 (30.1) |
| > 1 (n/%) | 69 (69.9) |
| < =3 (n/%) | 54 (54.5) |
| > 3 (n/%) | 45 (45.5) |
| Largest nodule size (cm) | 4.3 (2.1–8.3) |
| Portal vein invasion (n/%) | 29 (29.3) |
| Main portal vein invasion (n/%) | 8 (8.1) |
| First branch invasion (n/%) | 8 (8.1) |
| Second branch invasion (n/%) | 13 (13.1) |
| Hepatic vein invasion (n/%) | 17 (17.2) |
| ECOG performance status | |
| 0 (n/%) | 70 (70.7) |
| 1 (n/%) | 29 (29.3) |
| Child-pugh Stage | |
| A (n/%) | 91 (91.2) |
| B (n/%) | 8 (8.1) |
| BCLC Stage | |
| A (n/%) | 24 (24.2) |
| B (n/%) | 35 (35.4) |
| C (n/%) | 40 (40.4) |
| Laboratory Indexes | |
| WBC abnormal (n/%) | 31 (31.3) |
| RBC abnormal (n/%) | 16 (16.2) |
| ANC abnormal (n/%) | 26 (26.3) |
| HB abnormal (n/%) | 28 (28.3) |
| 80~ 100 g/L | 5 (5.1) |
| > 100 g/L | 23 (23.2) |
| PLT abnormal (n/%) | 28 (28.3) |
| 50~ 70 × 109/L | 19 (19.2) |
| > 70 × 109/L | 9 (9.1) |
| ALB abnormal (n/%) | 10 (10.1) |
| TP abnormal (n/%) | 20 (20.2) |
| TBIL abnormal (n/%) | 17 (17.2) |
| 21~ 34 μmol/L | 13 (13.1) |
| 34~ 51 μmol/L | 4 (4.0) |
| TBA abnormal (n/%) | 29 (29.3) |
| ALT abnormal (n/%) | 22 (22.2) |
| AST abnormal (n/%) | 31 (31.3) |
| 1~ 2ULN | 25 (25.2) |
| 2~3ULN | 6 (6.1) |
| ALP abnormal (n/%) | 19 (19.2) |
| BCr abnormal (n/%) | 10 (10.1) |
| BUN abnormal (n/%) | 9 (9.1) |
| AFP abnormal (n/%) | 55 (55.6) |
| 20.0~ 400 ng/ml | 21 (21.2) |
| > 400 ng/ml | 34 (34.3) |
| CEA abnormal (n/%) | 12 (12.1) |
| CA199 abnormal (n/%) | 19 (19.2) |
| Previous treatment | |
| cTACE (n/%) | 39 (39.4) |
| cTACE times | 1 (1~ 2) |
| Surgery (n/%) | 66 (66.7) |
| Systematic chemotherapy (n/%) | 5 (5.1) |
| Radiofrequency ablation (n/%) | 17 (17.2) |
| Targeted therapy (n/%) | 1 (1.0) |
| Chemoembolization reagents | |
| Adriamycin (n/%) | 4 (4.1) |
| Epirubicin (n/%) | 95 (95.9) |
Data was presented as count (%), mean ± standard deviation or median (25th–75th)
aTumor distribution: percentage of tumor in the whole liver. HBV Hepatic b virus, HCV Hepatic c virus, ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, WBC While blood cell, RBC Red blood cell, ANC Absolute neutrophil count, HB Hemoglobin, PLT Platelet, ALB Albumin, TP Total protein, TBIL Total bilirubin, TBA Total bile acid, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ALP Alkaline phosphatase, BCr Blood creatinine, BUN Blood urea nitrogen, AFP Alpha fetoprotein, CEA Carcino-embryonic antigen, CA199 Carbohydrate antigen199, cTACE Conventional transarterial chemo-embolization